These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 25538273)

  • 21. Few modifications of the Cobas Amplicor HIV Monitor 1.5 test allow reliable quantitation of HIV-1 proviral load in peripheral blood mononuclear cells.
    Lillo FB; Grasso MA; Lodini S; Bellotti MG; Colucci G
    J Virol Methods; 2004 Sep; 120(2):201-5. PubMed ID: 15288963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative detection of human immunodeficiency virus type 1 (HIV-1) proviral DNA in peripheral blood mononuclear cells by SYBR green real-time PCR technique.
    Gibellini D; Vitone F; Schiavone P; Ponti C; La Placa M; Re MC
    J Clin Virol; 2004 Apr; 29(4):282-9. PubMed ID: 15018857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel Assays for Measurement of Total Cell-Associated HIV-1 DNA and RNA.
    Hong F; Aga E; Cillo AR; Yates AL; Besson G; Fyne E; Koontz DL; Jennings C; Zheng L; Mellors JW
    J Clin Microbiol; 2016 Apr; 54(4):902-11. PubMed ID: 26763968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Herpes simplex virus type 2 (HSV-2) genital shedding in HSV-2-/HIV-1-co-infected women receiving effective combination antiretroviral therapy.
    Péré H; Rascanu A; LeGoff J; Matta M; Bois F; Lortholary O; Leroy V; Launay O; Bélec L;
    Int J STD AIDS; 2016 Mar; 27(3):178-85. PubMed ID: 25769886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy.
    Imamichi H; Crandall KA; Natarajan V; Jiang MK; Dewar RL; Berg S; Gaddam A; Bosche M; Metcalf JA; Davey RT; Lane HC
    J Infect Dis; 2001 Jan; 183(1):36-50. PubMed ID: 11106537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation between HIV-Specific CD8 cell production of interferon- gamma and plasma levels of HIV RNA in perinatally infected pediatric populations.
    Borkowsky W; Zhan MX; Chen SH; Ilmet T; Kaul A; Chandwani S; Rigaud M; Essajee S; Gruber C; Freedman A; Krasinski K
    J Infect Dis; 2004 Aug; 190(4):722-6. PubMed ID: 15272400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV-1 DNA burden in peripheral blood CD4+ cells influences disease progression, antiretroviral efficacy, and CD4+ T-cell restoration.
    Russell RR; Bowmer MI; Nguyen C; Grant MD
    Viral Immunol; 2001; 14(4):379-89. PubMed ID: 11792067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy.
    Zhang H; Dornadula G; Beumont M; Livornese L; Van Uitert B; Henning K; Pomerantz RJ
    N Engl J Med; 1998 Dec; 339(25):1803-9. PubMed ID: 9854115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy.
    Imamichi H; Dewar RL; Adelsberger JW; Rehm CA; O'Doherty U; Paxinos EE; Fauci AS; Lane HC
    Proc Natl Acad Sci U S A; 2016 Aug; 113(31):8783-8. PubMed ID: 27432972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Residual HIV-RNA levels persist for up to 2.5 years in peripheral blood mononuclear cells of patients on potent antiretroviral therapy.
    Fischer M; Günthard HF; Opravil M; Joos B; Huber W; Bisset LR; Ott P; Böni J; Weber R; Cone RW
    AIDS Res Hum Retroviruses; 2000 Aug; 16(12):1135-40. PubMed ID: 10954888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV RNA and HIV DNA in peripheral blood mononuclear cells are consistent markers for estimating viral load in patients undergoing long-term potent treatment.
    Burgard M; Izopet J; Dumon B; Tamalet C; Descamps D; Ruffault A; Vabret A; Bargues G; Mouroux M; Pellegrin I; Ivanoff S; Guisthau O; Calvez V; Seigneurin JM; Rouzioux C
    AIDS Res Hum Retroviruses; 2000 Dec; 16(18):1939-47. PubMed ID: 11153076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV Maintains an Evolving and Dispersed Population in Multiple Tissues during Suppressive Combined Antiretroviral Therapy in Individuals with Cancer.
    Rose R; Lamers SL; Nolan DJ; Maidji E; Faria NR; Pybus OG; Dollar JJ; Maruniak SA; McAvoy AC; Salemi M; Stoddart CA; Singer EJ; McGrath MS
    J Virol; 2016 Oct; 90(20):8984-93. PubMed ID: 27466425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
    Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A;
    J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peripheral blood Dendritic cells are not a major reservoir for HIV type 1 in infected individuals on virally suppressive HAART.
    Otero M; Nunnari G; Leto D; Sullivan J; Wang FX; Frank I; Xu Y; Patel C; Dornadula G; Kulkosky J; Pomerantz RJ
    AIDS Res Hum Retroviruses; 2003 Dec; 19(12):1097-103. PubMed ID: 14709246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of an affordable HIV-1 virological failure assay and antiretroviral drug resistance genotyping protocol.
    Bronze M; Aitken SC; Wallis CL; Steegen K; Stuyver LJ; de Wit TF; Stevens W
    J Virol Methods; 2013 Dec; 194(1-2):300-7. PubMed ID: 23994150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of distinct blood lymphocyte populations in human immunodeficiency virus type 1-infected subjects in the absence or presence of effective therapy.
    Derdeyn CA; Kilby JM; Miralles GD; Li LF; Sfakianos G; Saag MS; Hockett RD; Bucy RP
    J Infect Dis; 1999 Dec; 180(6):1851-62. PubMed ID: 10558941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy.
    Fourati S; Flandre P; Calin R; Carcelain G; Soulie C; Lambert-Niclot S; Maiga A; Ait-Arkoub Z; Tubiana R; Valantin MA; Autran B; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2014 Mar; 69(3):753-6. PubMed ID: 24187041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected children.
    Jeremy RJ; Kim S; Nozyce M; Nachman S; McIntosh K; Pelton SI; Yogev R; Wiznia A; Johnson GM; Krogstad P; Stanley K;
    Pediatrics; 2005 Feb; 115(2):380-7. PubMed ID: 15687448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts.
    Hocqueloux L; Avettand-Fènoël V; Jacquot S; Prazuck T; Legac E; Mélard A; Niang M; Mille C; Le Moal G; Viard JP; Rouzioux C;
    J Antimicrob Chemother; 2013 May; 68(5):1169-78. PubMed ID: 23335199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.